You are here

Amgen's new cholesterol drug falls short as sales driver

Biotech giant is anxious for Repatha to make up for slowing sales of older ones

San Francisco

AMGEN Inc's new cholesterol drug is still struggling to gain traction, missing analysts' estimates at a time when the biotechnology giant is anxious for its newer drugs to make up for slowing sales of its older ones.

Sales of the drug, called Repatha, for the first

sentifi.com

Market voices on:

Powered by GET.comGetCom